Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 3% during mid-day trading on Monday . The company traded as low as $35.26 and last traded at $35.39, with a volume of 1,159,260 shares changing hands. The stock had previously closed at $36.49.

A number of research analysts recently issued reports on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $44.00 price target on shares of Acadia Pharmaceuticals in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Acadia Pharmaceuticals in a report on Monday. Vetr raised Acadia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $41.00 price target for the company in a report on Monday. Aegis cut Acadia Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the company from $54.00 to $41.00 in a report on Friday. They noted that the move was a valuation call. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $49.00 price target on shares of Acadia Pharmaceuticals in a report on Friday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Acadia Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $45.60.

The stock has a 50-day moving average of $34.58 and a 200-day moving average of $29.26. The company’s market capitalization is $3.59 billion.

Acadia Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.14. The firm earned $0.97 million during the quarter, compared to the consensus estimate of $0.71 million. The business’s quarterly revenue was up 96900.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.39) earnings per share. Equities research analysts predict that Acadia Pharmaceuticals Inc. will post ($2.20) earnings per share for the current fiscal year.

In other news, EVP Glenn Baity sold 4,057 shares of the stock in a transaction on Monday, July 11th. The stock was sold at an average price of $35.00, for a total transaction of $141,995.00. Following the sale, the executive vice president now directly owns 66,978 shares of the company’s stock, valued at approximately $2,344,230. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Other hedge funds recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC raised its stake in Acadia Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 77,957 shares of the biopharmaceutical company’s stock valued at $2,779,000 after buying an additional 466 shares during the period. California Public Employees Retirement System raised its stake in Acadia Pharmaceuticals by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 194,000 shares of the biopharmaceutical company’s stock valued at $6,916,000 after buying an additional 900 shares during the period. Rhumbline Advisers increased its stake in shares of Acadia Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 74,690 shares of the biopharmaceutical company’s stock valued at $2,663,000 after buying an additional 1,715 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Acadia Pharmaceuticals by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 150,666 shares of the biopharmaceutical company’s stock valued at $5,372,000 after buying an additional 1,739 shares in the last quarter. Finally, BlackRock Advisors LLC increased its stake in shares of Acadia Pharmaceuticals by 1.6% in the fourth quarter. BlackRock Advisors LLC now owns 323,776 shares of the biopharmaceutical company’s stock valued at $11,543,000 after buying an additional 5,240 shares in the last quarter.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.